In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, deeply weird. Credit...Illustration by Pablo Delcan and Danielle Del Plato ...
“Let’s get this party started!” That was Ilia Malinin’s message to the ticket-holders on the Hub Vision screen before he took the ice at TD Garden on Thursday afternoon. The men’s short program at the ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
SIMI VALLEY, California.—The White House has greenlit a plan to design and build a frigate domestically as part of its proposed “Golden Fleet,” Navy Secretary John Phelan announced at the Reagan ...
Brigham and Women’s Hospital nurses are speaking out in opposition to plans to merge the hospital’s burn unit with Mass General’s in 2026, which they argue damages generations of institutional ...
COLUMBUS, Ohio -- Ohio may start paying its small towns and villages to merge. A new bill at the statehouse would create a $25 million grant program to reward local governments that combine into one ...
This guest essay reflects the views of Marc Herbst, the executive director of the Long Island Contractors' Association. This month, Long Island achieved an important victory: ensuring that critical ...
Google's generative AI filmmaking program Flow has reached a milestone. The tech giant confirmed exclusively to CNET that Flow creators have produced over 100 million AI videos in the program. Thanks ...
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Andres Almiray, a serial open-source ...
Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results